Hypertriglyceridemia: Rx OM-3s
The FDA-approved Rx OM-3s have been reviewed extensively [
15‐
17] and include various combination products containing both DHA and EPA (Lovaza
TM: GlaxoSmithKline, Research Triangle Park, NC, USA; Epanova
TM: AstraZeneca, Wilmington, DE, USA; Omtryg
TM: Trygg Pharma, Arlington, VA, USA; Vascepa
TM: Amarin Pharma, Inc., Bedminster, NJ, USA) [
8]. These Rx OM-3 products have clinically proven efficacy and safety and are indicated as an adjunct to dietary interventions to reduce TG in adults with severe hypertriglyceridemia (TG ≥ 500 mg/dl) at 4 g/day. However, evidence is lacking on the potential benefit in the reduction of pancreatitis risk in this patient population [
8,
18‐
20]. The American Heart Association (AHA) recently issued a science advisory on OM-3s for treatment of hypertriglyceridemia, stating that Rx OM-3s, at 4 g/day, produce TG reductions of approximately 20–30% in patients with high TG (200–499 mg/dl) and reductions of ≥ 30% in those with higher TG (≥ 500 mg/dl), noting LDL-C increases with DHA-containing products in the latter group [
21]. The 2019 AHA advisory concluded that Rx OM-3s (DHA + EPA or EPA-only) are clinically useful for reducing TG after any underlying causes have been addressed and diet and lifestyle strategies implemented, either as monotherapy or an adjunct to other TG-lowering therapies [
21].
Role in CVD
The potential impact of OM-3 fatty acid supplementation on CVD risk and outcomes in both primary and secondary prevention populations has been the subject of extensive study [
22]. A systematic review of 79 clinical studies of OM-3 dietary supplementation concluded that, based on high-quality evidence, EPA and DHA “do not have important positive or negative effects” on either mortality or CV events. In addition, based on moderate-quality evidence, it was concluded that OM-3s had little or no effect on other measures of CV health in primary or secondary prevention [
22]. A 2017 AHA science advisory on OM-3 supplements for prevention of CVD did not recommend OM-3s for prevention of CVD in patients with diabetes mellitus and prediabetes, noting a lack of consensus on the recommendation for patients at high CVD risk, although use in those with established coronary heart disease (e.g., past myocardial infarction) was considered reasonable for potential modest benefit [
23]. Also of interest is a meta-analysis of eight randomized clinical studies of patients with hypertension that concluded that fish oil supplements had a statistically significant, but relatively modest effect on blood pressure compared with blood pressure-lowering drugs and thus should not be considered an alternative to guideline-recommended blood pressure-lowering medication for patients with elevated CV risk [
24]. Another meta-analysis of ten trials concluded that there was no support for supplementation of OM-3s at approximately 1 g/day in people with history of coronary heart disease for secondary prevention of CVD events [
25]. Despite extensive interest and research, there is a lack of consistent support for OM-3 dietary supplements in CV risk reduction. As the potential for Rx OM-3s in CV risk reduction appears promising, it is instructive to review the recently published OM-3 CVOTs.
Key OM-3 CVOTs
The results of the three most recent, large, randomized, placebo-controlled CVOTs evaluating the impact of OM-3 products are summarized in Table
1 [
9‐
11]. Although the primary CV endpoint was achieved by Rx EPA in REDUCE-IT, the DHA + EPA OM-3 combination formulations did not achieve their primary CV endpoints in either the VITAL or ASCEND trials. The lack of CV benefits with the DHA + EPA OM-3 combination was a disappointing finding given the promise of earlier reports with dietary supplements in prior clinical trials. In particular, the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI)-Prevenzione study reported that use of a DHA + EPA OM-3 combination significantly decreased the rate of death, nonfatal myocardial infarction, and stroke in patients who had experienced a heart attack within the prior 3 months [
26]. Similarly, among patients with heart failure, the GISSI-HF study showed that a DHA + EPA OM-3 combination reduced all-cause mortality and CV hospital admissions [
27]. Potential reasons for the findings of the earlier GISSI study not being borne out in VITAL and ASCEND could be differences in study design and populations, the agents and doses utilized, differences in use of contemporary medical therapy, including statin use, and potential biases in the older studies [
22].
In REDUCE-IT, primary CV endpoint events (i.e., CV death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) occurred in 17.2% of patients in the high-dose Rx EPA (icosapent ethyl) group compared with 22.0% of patients receiving placebo [hazard ratio 0.75 [95% confidence interval (CI) 0.68–0.83;
P < 0.001] [
9]. This corresponded to an absolute difference of 4.8% (95% CI 3.1–6.5) between groups and a number needed to treat of 21 (95% CI 15–33). Based on the results of REDUCE-IT, icosapent ethyl is now also indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated TG (≥ 150 mg/dL) and established CVD or diabetes mellitus and ≥ 2 additional risk factors for CVD [
8]. The potential benefit of an EPA-only Rx product for CV risk reduction was first reported in the Japan EPA Lipid Intervention Study (JELIS) [
28], which found a significant 19% relative risk reduction in major coronary events with high-purity EPA plus statin treatment compared with a statin alone in Japanese patients (hazard ratio 0.81; 95% CI 0.69–0.95;
P = 0.011).
Differences in OM-3 fatty acid composition may also have contributed to disparate CVOT findings. It is possible that, beyond TG lowering, pleiotropic effects of EPA on other lipids/lipoproteins, inflammation, oxidation, phospholipid membranes, and plaque [
2] may have contributed to the CV risk reduction demonstrated in JELIS, REDUCE-IT, and other smaller trials [
29]. In light of the recent OM-3 dietary supplement CVOT data [
25], the European Medicines Agency Committee for Medicinal Products for Human Use concluded that DHA + EPA combination formulations are not effective in preventing further heart and vascular problems in patients who have had a myocardial infarction and recommended removal of authorization for such use [
30]. More recently, the 2019 European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) task force guidelines recommend that, in high-risk patients with TG between 135 and 499 mg/dl despite statin treatment, the EPA-only OM-3 icosapent ethyl (2 × 2 g/day) be considered in combination with statins [
31]. Similarly, in the USA, the 2019 National Lipid Association (NLA) position statement recommends treatment with icosapent ethyl for ASCVD risk reduction for patients aged ≥ 45 years with clinical ASCVD or ≥ 50 years with type 2 diabetes and ≥ 1 additional risk factor who have TG 135–499 mg/dl on maximally tolerated statin, with or without ezetimibe [
32].
Additional factors that may influence CVOT findings include OM-3 dose, definition of primary composite CV endpoint, and study population. The total daily dose of OM-3 was much lower in VITAL and ASCEND (< 1 g/day total OM-3 per each 1-g capsule) than in REDUCE-IT (4 g/day high-purity Rx EPA). GISSI-Prevenzione and GISSI-HF had positive findings despite relatively low doses of OM-3s (≤ 1 g daily); however, these studies may have had inherent biases, and GISSI-Prevenzione is a much older study, conducted before the modern statin and contemporary medical era. The primary composite CV endpoint varied between the studies (Table
1, see footnote); for example, in REDUCE-IT, coronary revascularization and unstable angina were included, in addition to CV death, nonfatal myocardial infarction, and nonfatal stroke. Differences in study populations should also be considered. REDUCE-IT evaluated the impact of high-dose Rx EPA treatment in patients with established ASCVD and in high-risk primary prevention patients with elevated TG (135–499 mg/dl) despite optimized LDL-C (41–100 mg/dl) on stable statins. ASCEND and VITAL evaluated patients with diabetes without established ASCVD and a primary prevention population, respectively. Among the positive CVOTs, only REDUCE-IT carries sufficient scientific weight based on current standards of practice, and thus its results may become an important potential consideration in the setting of patients who have or are at high risk for ASCVD. Of note, the treatment group in REDUCE-IT had a higher rate of hospitalization for atrial fibrillation or flutter compared with the control group (3.1% vs. 2.1%;
P = 0.004). However, those taking icosapent ethyl did have a significantly lower risk of stroke compared with the control group (hazard ratio 0.72; 95% CI 0.55–0.93;
P = 0.01) [
9]. A nonsignificant increase in the risk of bleeding, without an increased risk in life-threatening bleeding, was also observed in the icosapent ethyl group. As such, periodic monitoring is advised for patients taking icosapent ethyl with other medications that may increase the risk for bleeding. Another CVOT of interest is the ongoing STRENGTH trial, which is evaluating an Rx DHA + EPA combination (OM-3 carboxylic acids) in patients with established ASCVD, diabetes with an additional risk factor, or high risk of a future ASCVD event, who are on optimal statin therapy with elevated TG (≥ 180–< 500 mg/dl) [
33].
Non-CV Conditions
Consumers may choose to use OM-3 dietary supplements for potential expectations related to a variety of non-CV conditions, including arthritis, brain health, eye health, maternal–fetal/infant health, and more. Despite the multiple purported benefits, systematic reviews and meta-analyses have found the clinical evidence for OM-3 dietary supplements in these health conditions to be insufficient, inconsistent, or negative [
34‐
39]. For example, a systematic review and meta-analysis of 42 randomized clinical trials of OM-3 dietary supplementation for arthritis noted a moderate benefit among patients with rheumatoid arthritis, but insufficient evidence to determine the effect in other types of arthritis [
34]. In terms of brain health, a systematic review of seven clinical studies of OM-3 dietary supplements for Alzheimer’s disease (AD) found that cognitive improvement was observed in some cases, particularly in very mild AD; however, the collective evidence was insufficient to support OM-3s in the treatment of AD [
35]. Similarly, a meta-analysis of three high-quality randomized controlled trials in cognitively healthy patients > 60 years of age concluded that OM-3 dietary supplementation did not improve cognitive function [
36]. Regarding eye health, a review of dietary interventions for age-related macular degeneration (AMD) found that despite observational studies that suggested reduced risk of progression to advanced AMD, rigorous randomized controlled trials of OM-3s failed to show a decreased risk of advanced AMD development [
37]. A large systematic review of OM-3 dietary supplementation [
38] examined 143 studies in pregnant or breastfeeding women or infants and found small generally positive effects on birth weight and length of gestation, but concluded that OM-3 dietary supplementation did not have any consistent evidence of effects on peripartum maternal health outcomes or on infant health outcomes such as brain and eye health. Likewise, there was insufficient evidence to draw conclusions regarding the impact of OM-3s on developmental disorders/disabilities in children.